<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AE6D10A2-CE96-4CD3-9028-D1576E34E910"><gtr:id>AE6D10A2-CE96-4CD3-9028-D1576E34E910</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Fisher</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0700861"><gtr:id>2E4E9CF5-0680-4C04-BE07-7DA2D9E88426</gtr:id><gtr:title>Effect of Airway Microenvironment on TGF-beta driven Epithelial to Mesenchymal Cell Transition in the Transplanted Lung</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700861</gtr:grantReference><gtr:abstractText>Some patients dying of lung disease are lucky enough to get a new lease of life with a lung transplant. Tragically, half of them will die within 5 years of having their transplant because their new lungs fail. The new lungs are destroyed by a scarring process which blocks the small bronchial tubes. This process is called obliterative bronchiolitis or OB. 
We will try to find out if the lining cells of the lungs? bronchial tubes, (called epithelial cells), are vital in developing OB. Damaged lining cells are normally repaired in healthy individuals. However, if the damage is frequent or continuous, these cells can change their behaviour to become specialist scarring cells (called mesenchymal cells). Mesenchymal cells are responsible for depositing scar tissue. We will test if repeated damage to the lining cells after lung transplant makes them change into specialist cells which deposit scar tissue which could block the small bronchial tubes. 
In this study, we will take lining cells from patients who have had a lung transplant and grow them in the laboratory. We will then investigate if growth factors in the lung when combined with danger signals released at times of injury can drive the change from lining cells to scarring cells. 
This is important because if we understand how this change occurs, it may be possible to block it and prevent lining cells from changing behaviour. The hope would be to develop new treatments which protect the bronchial tubes from scarring. This would greatly improve long term survival in patients who have had a lung transplant.</gtr:abstractText><gtr:technicalSummary>Survival after lung transplantation at only 50% at 5 years is much poorer than after other solid organ transplants. The lung allograft fails due to the development of an obliterative bronchiolitis (OB), a progressive condition characterised by airways obstruction. Associations between OB and inflammatory insults to the lung have been identified, yet the mechanism linking airway epithelial cell injury to airway fibrosis and remodelling after lung transplantation remains elusive. 
This proposal will evaluate if epithelial to mesenchymal transition (EMT), a change in epithelial cell phenotype and function driven by TGFbeta, might represent a final common pathway to fibrosis in the injured airway and act as a valuable therapeutic target.The specific aims are:
(1)To characterise TGFbeta-driven EMT in primary airway epithelial cells cultured from lung transplant recipients. Morphological, protein expression and functional changes in cells undergoing EMT will be characterised using confocal microscopy, western blotting and realtime PCR for our panel of EMT markers. Zymography and matrigel invasion assays will assess functional matrix metalloproteinase activity.
(2)To explore how TNFalpha augments TGFbeta driven EMT by assessing change in cell surface expression of the alphaVbeta6 integrin and the decoy TGFbeta receptor BAMBI. 
(3)To examine intracellular signalling crosstalk between the MAPkinase and Smad signalling pathways in cells undergoing EMT with specific attention to the TAK-1 ? p38 ? NFkB pathway. Using phosphospecific antibodies and selective blockade with peptide inhibitors, SiRNA and RNAi, I will dissect out the relative contributions from each pathway to the EMT phenotype.
(4)To conduct a longitudinal observational study in 60 lung recipients from the time of transplant by measuring EMT markers on epithelial cells harvested by brushing at serial bronchoscopies. Bronchoalveolar lavage (BAL) fluid from recipients with and without OB will be assessed for its ability to drive EMT in normal airway epithelium. By selective blockade of growth factors and pro-inflammatory signals in the BAL we will determine their relative contribution to the process. 
(5)To establish co-cultures of stimulated alveolar macrophages and airway epithelial cells to determine if interaction between these cells is important in driving EMT. The effect of anti-TNFalpha approaches and exogenous latent TGFbeta will be assessed in the model. 
The scientific expertise in my institution together with my clinical links to the largest lung transplant programme in UK places me in a unique position to address these aims effectively and move towards improving survival in lung transplant recipients.</gtr:technicalSummary><gtr:fund><gtr:end>2011-02-28</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>361752</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Respiratory Medicine</gtr:department><gtr:description>MRC/ABPI COPD MAP Consortium</gtr:description><gtr:id>171CDE4A-D567-49D6-BBB0-35FB633F978C</gtr:id><gtr:impact>Unified SOPs
Transfer of tissue and cells
Liason with Industry partners in consortium</gtr:impact><gtr:partnerContribution>Recruitment of patients with COPD undergoing lung resection. isolation of primary cells from diseased lung tisssue. Laboratory experiments using this material.
Transfer of cell material to other partners in consortium</gtr:partnerContribution><gtr:piContribution>Recruitment of patients with COPD undergoing lung transplantation. isolation of primary cells from diseased lung tisssue. Laboratory experiments using this material.
Transfer of cell material to other partners in consortium</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>breathtakers patient support group charity</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C8FC5F0A-1903-4347-992C-38E75A4C58BC</gtr:id><gtr:impact>meeting hosted in Newcastle for membetrs of the breathtakers charity patient support group for obliterative bronchiolitis

valuable interaction for both my research team and visiting charity group</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mini-medical School initative. Newcastle</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9C72F43B-56F4-4199-BAF2-8AC2891B2DB5</gtr:id><gtr:impact>80 individuals attended a session run as the opening of the mini-medical school which compises 6 weeks of lectures on a thursday evening.

N/A</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Third Age</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>43ED9309-3691-42C5-AED7-A14054C0FA13</gtr:id><gtr:impact>150 members of the public attended the University of the Third Age which is targeted at Older people in society

Excellent feedback</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MedImmune Sponsored CASE studentship</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>ACD70E30-2849-4C2D-A172-6371A198DFD7</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC CASE PhD studentship</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>5B16A47F-2CDD-45E1-9A8F-D96E8D8BF483</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>FP7 Marie Curie International Outgoing Fellowship</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Marie Curie Actions</gtr:fundingOrg><gtr:id>E2B612EC-C02A-46A5-8D9A-63E516129FA2</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited to join working group of chronic allograft dysfunction after lung transplant to produce a guideline - organised by ATS, ISHLT and ERS</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>EED08BA8-9E16-4878-B622-E666DC294DBB</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Lung tissue removed at the time of lung transplantation or at the time of lung resection for cancer is now collected regularly and is processed to provide epithelial cells, fibroblasts and monocytes for culture.</gtr:description><gtr:id>BC00AD70-0057-4B28-9AB4-7F282F5E3E33</gtr:id><gtr:impact>This provides a very valuable resource of lung tissue from advanced lung diseases such as pulmonary fibrosis and COPD. This has allowed collaborations with other major groups within the UK.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Biobank of diseased and normal lung tissue</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EA3B3C08-DEC0-45B8-A7BA-8623CF564C39"><gtr:id>EA3B3C08-DEC0-45B8-A7BA-8623CF564C39</gtr:id><gtr:title>The critical role of TAK1 in accentuated epithelial to mesenchymal transition in obliterative bronchiolitis after lung transplantation.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ed30102978c38099296ea3d33e86338b"><gtr:id>ed30102978c38099296ea3d33e86338b</gtr:id><gtr:otherNames>Gardner A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3035ECC6-D145-418F-BC6A-270B65D0FBD9"><gtr:id>3035ECC6-D145-418F-BC6A-270B65D0FBD9</gtr:id><gtr:title>IL-1a released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d6cfd91f59b8d8c64fab870754004afa"><gtr:id>d6cfd91f59b8d8c64fab870754004afa</gtr:id><gtr:otherNames>Suwara MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1B8C32F2-E58D-4939-BF5D-1941278DD61C"><gtr:id>1B8C32F2-E58D-4939-BF5D-1941278DD61C</gtr:id><gtr:title>Transforming Growth Factor-?1 (TGF-?1) Driven Epithelial to Mesenchymal Transition (EMT) is Accentuated by Tumour Necrosis Factor a (TNFa) via Crosstalk Between the SMAD and NF-?B Pathways.</gtr:title><gtr:parentPublicationTitle>Cancer microenvironment : official journal of the International Cancer Microenvironment Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44cc7212079edf08d8e5783c09e153a1"><gtr:id>44cc7212079edf08d8e5783c09e153a1</gtr:id><gtr:otherNames>Borthwick LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1875-2284</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0374D838-1B48-4D65-88A8-BCED62F42852"><gtr:id>0374D838-1B48-4D65-88A8-BCED62F42852</gtr:id><gtr:title>Inflammation and epithelial to mesenchymal transition in lung transplant recipients: role in dysregulated epithelial wound repair.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44cc7212079edf08d8e5783c09e153a1"><gtr:id>44cc7212079edf08d8e5783c09e153a1</gtr:id><gtr:otherNames>Borthwick LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25E7672E-716D-4AD4-A613-B564CF6A289C"><gtr:id>25E7672E-716D-4AD4-A613-B564CF6A289C</gtr:id><gtr:title>Lung epithelial wound healing in health and disease.</gtr:title><gtr:parentPublicationTitle>Expert review of respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ed30102978c38099296ea3d33e86338b"><gtr:id>ed30102978c38099296ea3d33e86338b</gtr:id><gtr:otherNames>Gardner A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1747-6348</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6E38FBB0-44F4-4919-B719-D066C888E9DA"><gtr:id>6E38FBB0-44F4-4919-B719-D066C888E9DA</gtr:id><gtr:title>Pseudomonas aeruginosa accentuates epithelial-to-mesenchymal transition in the airway.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44cc7212079edf08d8e5783c09e153a1"><gtr:id>44cc7212079edf08d8e5783c09e153a1</gtr:id><gtr:otherNames>Borthwick LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6D462624-DEBA-43F0-9177-726BC3FCBD38"><gtr:id>6D462624-DEBA-43F0-9177-726BC3FCBD38</gtr:id><gtr:title>Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a TGF-?1-dependent mechanism.</gtr:title><gtr:parentPublicationTitle>Free radical biology &amp; medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c3ac1ce2ea339113f0f0a3838ae1d725"><gtr:id>c3ac1ce2ea339113f0f0a3838ae1d725</gtr:id><gtr:otherNames>Gorowiec MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0891-5849</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8A36FE6B-5C48-4AB5-8E66-C00CA6858C91"><gtr:id>8A36FE6B-5C48-4AB5-8E66-C00CA6858C91</gtr:id><gtr:title>Epithelial to mesenchymal transition (EMT) and airway remodelling after human lung transplantation.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44cc7212079edf08d8e5783c09e153a1"><gtr:id>44cc7212079edf08d8e5783c09e153a1</gtr:id><gtr:otherNames>Borthwick LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A2DC95DD-53F3-4F87-929B-00B1666E1540"><gtr:id>A2DC95DD-53F3-4F87-929B-00B1666E1540</gtr:id><gtr:title>Pseudomonas aeruginosa Induced Airway Epithelial Injury Drives Fibroblast Activation: A Mechanism in Chronic Lung Allograft Dysfunction.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44cc7212079edf08d8e5783c09e153a1"><gtr:id>44cc7212079edf08d8e5783c09e153a1</gtr:id><gtr:otherNames>Borthwick LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AA3E682C-1D76-4E35-A90F-BD255109CE64"><gtr:id>AA3E682C-1D76-4E35-A90F-BD255109CE64</gtr:id><gtr:title>Cytokine mediated tissue fibrosis.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44cc7212079edf08d8e5783c09e153a1"><gtr:id>44cc7212079edf08d8e5783c09e153a1</gtr:id><gtr:otherNames>Borthwick LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/92A149BB-5588-40E0-9988-4603ABAEC162"><gtr:id>92A149BB-5588-40E0-9988-4603ABAEC162</gtr:id><gtr:title>TNFa from classically activated macrophages accentuates epithelial to mesenchymal transition in obliterative bronchiolitis.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44cc7212079edf08d8e5783c09e153a1"><gtr:id>44cc7212079edf08d8e5783c09e153a1</gtr:id><gtr:otherNames>Borthwick LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700861</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>